


Curriculum vitae

Name: Seemal R. Desai, MD, FAAD
Office Address: Innovative Dermatology, PA
5425 W. Spring Creek Pkwy, Ste 265
Plano, TX 75024
8080 Independence Pkwy, Ste 150
Plano, TX 75025
Work Phone: (214) 919-3500
Work E-Mail: seemald@yahoo.com
Work Fax: 214-919-3501
Place of Birth: Birmingham, Alabama



Handwritten signature and date: 3/25/2021

Education

Year	Degree (Honors)	Field of Study (Thesis advisor for PhDs)	Institution
2000	B.A.	Bachelor of Arts, Chemistry & French (Dual Major)	Emory University, Atlanta, GA
2005	M.D. (Magna Cum Laude with Honors)	Medicine	Morehouse School of Medicine, Atlanta, GA

Postdoctoral Training

Year(s)	Titles	Specialty/Discipline	Institution
2005-2006	Internship	Internal Medicine	Morehouse School of Medicine – Department of Internal Medicine, Atlanta, GA
2006-2009 2008-2009	Residency Chief Resident	Dermatology	University of Alabama at Birmingham-School of Medicine (UAB), Birmingham, AL

Faculty Academic Appointments

Year(s)	Academic Title	Department	Academic Institution
2010-Present	Clinical Assistant Professor	Dermatology	University of Texas Southwestern Medical Center at Dallas

Current Licensure and Certification

Licensure

Texas State Medical License – Current and Active

Alabama State Medical License – Current and Active

Board and Other Certification

Diplomate, American Board of Dermatology – Current and Active

Board Certified Dermatologist

Honors and Awards

Year	Name of Honor/Award	Awarding Organization
2002-2003	AT&T Educational Award	
2002-2003	Bushnell Scholarship	Morehouse School of Medicine
2003	Aventis Minority Medical Scholar	American Academy of Neurology Foundation
2003-2004	Merit Scholarship	Morehouse School of Medicine
2003-2004	George W. and Pearl D. Strickland Scholar	Community Foundation of Atlanta
2003-2004	Pfizer Minority Medical Scholar	Pfizer Pharmaceuticals
2004-2005	Datatel Scholar	Datatel Corporation
2004-2005	George W. and Pearl D. Strickland Scholar	Community Foundation of Atlanta
2006	National Leadership Award	American Medical Association Foundation
2007	French Society of Dermatology	Annual Meeting Scholarship Award
2011	Best Doctors in Collin County	D Magazine
2012	Best Doctors in Collin County	D Magazine
2013	Best Doctors in Dallas & Best Doctors in Collin County	D Magazine
2014	Best Doctors in Dallas & Best Doctors in Collin County	D Magazine
2014	Presidential Citation - In recognition of years of service representing our specialty and the American Academy of Dermatology Association as the Young Physician Section Delegate to the American Medical Association	American Academy of Dermatology
2015	Best Doctors in Collin County	D Magazine
2015, 2016	Presidential Citation - In recognition of significant contributions and	American Academy of Dermatology

	dedication to promoting excellence in clinical dermatology.	
2016	Best Doctors in Collin County	D Magazine
2017	Best Doctors in Dallas & Best Doctors in Collin County	D Magazine
2018	Best Doctors in Dallas & Best Doctors in Collin County	D Magazine
2020	Presidential Citation - In recognition for your efforts to preserve in-office medication preparation.	American Academy of Dermatology
2019	Best Doctors in Dallas & Best Doctors in Collin County	D Magazine
2020	Best Doctors in Dallas & Best Doctors in Collin County	D Magazine

Appointments at Hospitals/Affiliated Institutions

<u>Current</u>			
Year(s)	Position Title	Department/Division	Institution
2010–Present	Attending Physician	Dermatology	Parkland Memorial Hospital Dallas, TX

Other Professional Positions [*Industry, foundation, private practice*]

Year(s)	Position Title	Institution
7/2009 – 7/2011	Dermatologist	Center for Skin & Cosmetic Dermatology, Dallas/Ft. Worth, TX
10/2011 – Present	President & Medical Director	Innovative Dermatology, PA, Plano, TX

Professional Societies

Dates	
2013-Present	Skin of Color Society - Immediate Past President, 2019-present - President, 2017-2019 - Secretary/Treasurer, 2015-2017 - Trustee, Board of Trustees, 2013-2015
2014-Present	Texas Dermatological Society - Immediate Past President, 2018-2019 - President, 2017-2018 - Board of Directors, 2014-2017
2009-Present	Dallas/Ft. Worth Dermatological Society - President, 2013 - Secretary/Treasurer, 2011-2012
2007-Present	American Academy of Dermatology (AAD) - Member, AHTF on COVID-19, 2020-present - Member, Executive Committee, Board Elected Rep, 2020-present - Director, Board of Directors, 2017-present - Chair, Leadership Development Steering Committee, 2017-2019 - Chair, AAD Compounding Workgroup, 2017-present - Member, AHTF on Corporate Positioning, 2018-present - Member, AHTF on Executive Director/CEO Search, 2019-present - Member, AHTF on Reimagining the Summer Meeting, 2019-present - Member, Healthcare Finance Committee, 2016-present - Deputy Chair, Healthcare Finance Committee, 2019-present - Deputy Chair, Leadership Development Steering Committee, 2015-2017 - Director, SkinPAC Board of Directors, 2016-present - Member, Grassroots Advocacy Workgroup, 2014-present - Member, Leadership Development Steering Committee, 2014-present

	<ul style="list-style-type: none"> - Director, SkinPAC Board of Directors, 2013 - Member, AHTF on Physician Industry Relations, 2013 - Member, Congressional Policy Committee, 2012-2016, 2017-present - Member, Grassroots Advocacy Workgroup, 2012-present - Alternate Delegate, American Academy of Dermatology to the American Medical Association, 2011-present - Fellow, American Academy of Dermatology, January 2010-Present - Committee Member, Residents and Fellows Committee, February 2007-May 2009
2009-Present	<p>Dermatology Foundation</p> <ul style="list-style-type: none"> - Vice-Chair, Leader's Society, 2013-present
2001-Present	<p>American Medical Association (AMA)</p> <ul style="list-style-type: none"> - Alternate Delegate, American Academy of Dermatology to AMA, 2015-present - Delegate, American Academy of Dermatology to the AMA-YPS, 2011-2015 - Delegate, Texas Medical Association Young Physicians Section to the AMA-YPS, 2010-2011 - Delegate, American Academy of Dermatology to the AMA, 2008-2009 - Vice-Chair, Governing Council, AMA- Resident and Fellow Section, 2007-2008 - Member-At-Large, Governing Council, AMA-Resident and Fellow Section, 2006-2007 - Delegate, Medical Association of Georgia, AMA-RFS House of Delegates, 2005-2006 - Delegate, AMA House of Delegates, 2004-2005 - Alternate Delegate, AMA House of Delegates, 2003-2004 - Council Representative, Minority Issues Committee, 2003-2004 - Legislative Awareness Chair, Morehouse School of Medicine Chapter, 2002-2003 - Member, AMA-Resident and Fellows Section (RFS), 2005-2009 - Member, AMA-Minority Affairs Consortium, 2001-2009 - Member, American Medical Association Political Action Committee, 2001-present
2009-Present	<p>American Society of Dermatologic Surgery</p> <ul style="list-style-type: none"> - Member, Policy Priorities Workgroup, 2020-present - Member, Federal Affairs Workgroup, 2015-2019
2009-Present	<p>Texas Medical Association (TMA)</p> <ul style="list-style-type: none"> - Delegate, American Medical Association YPS, 2009-2010
2003-2005	<p>Medical Association of Georgia (MAG)</p> <ul style="list-style-type: none"> - Delegate, Georgia Delegation to the American Medical Association, 2004-2005 - State President, Medical Association of Georgia, Medical Student Section, 2003-2004 - Chairman, Executive Council, Medical Student Section, 2003-2004 - Alternate Delegate, Georgia Delegation to the American Medical Association, 2003-2004
2006-Present	<p>Women's Dermatologic Society (WDS)</p> <ul style="list-style-type: none"> - Member, Board of Directors, 2020-present - Member, Legacy Council, 2020-present - Member, Program Committee, 2017-present

	- Member, WDS Journal Task Force, 2016-2017 - Member, Fundraising Committee, 2014-2017
2009-Present	Dallas County Medical Society - Member, Communications Committee, 2009-present
2012-Present	International Advisory Committee, Asian Society of Pigment Cell Research
2013-Present	Noah Worcester Dermatologic Society
2015-Present	Pigmentary Disorders Society - International Advisory Board

Editorial Activities

Year(s)	Journal Name
<u>Associate Editor</u>	
2015-Present	<i>Journal of Clinical and Aesthetic Dermatology</i>
2015-Present	<i>Pigment International</i>
<u>Editorial Board</u>	
2013-Present	<i>Practical Dermatology</i>
2014-Present	<i>Pigment International</i>
2014-Present	<i>Journal of Clinical and Aesthetic Dermatology</i>
2015-Present	<i>Dermatologic Therapeutics</i>

Clinical Trials

Served as a Primary Investigator on numerous clinical research trials:

AbbVie December 2011- present

ESPRIT Psoriasis Registry Trial and Database for Psoriasis patients outcomes data.

ESPRIT is a 10 year registry of patients taking HUMIRA® for Psoriasis

AbbVie January 2013- August 2020

Hidradenitis Suppurativa clinical registry trial

An Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult and Adolescent Patients with Hidradenitis Suppurativa – UNITE

Tolmar June 2013 – Nov 2013

Protocol TOL2665A: A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing TOLMAR Azelaic Acid Gel, 15% to Reference Listed Drug in the Treatment of Rosacea

Perrigo June 2015 – August 2015

Protocol PRG-NY-15-002: A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo New York's Ingenol Mebutate Topical Gel 0.05% to Leo Pharma Inc. 'Picato' Topical Gel 0.05%, and Both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis on the Trunk and Extremities

Watson May 2015 – April 2016

Protocol SYM 2014-03: A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Pimecrolimus Cream, 1% and Reference Listed Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis

Promius July 2015 – April 2016

Protocol DFD06-CD-005: A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate Plaque Psoriasis of trunk and extremities for 14 Days.

Dermira July 2015 – January 2016

Protocol DRM-HH04: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Efficacy and Safety Study of XXX in Subjects with Axillary Hyperhidrosis

Dermira July 2015 – March 2017

Protocol DRM04-HH06: An open-label study assessing long term safety of DRM04 in subjects with primary axillary hyperhidrosis *Seemal R. Desai, MD, FAAD ACRC Trials, Updated 12JAN2021*

Teva November 2015 – February 2016

Protocol SYM2015-01: A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% (Teva Pharmaceuticals USA, Inc.) to Solaraze (diclofenac sodium) Gel, 3% (Fougera Pharmaceuticals Inc.) in the Treatment of Actinic Keratosis on the Face or Bald Scalp

Novan April 2016 –September 2016

Protocol NI-AC 302: A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily SB204 and Vehicle Gel in the Treatment of Acne Vulgaris

Foamix June 2016 – January 2018

Protocol FX2014-04: A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris

AbbVie H15-547 June 2016-2017

'A Cross-sectional Observational study evaluating clinical specialty setting as determinant of management in Patients with Psoriatic Arthritis'

Symbio August 2016 – July 2017

Protocol SYM 2016-01: A Double-Blind, Randomized, Parallel-Group, Vehicle- Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Par Pharmaceutical Inc.'s

Pimecrolimus Cream, 1% and Reference Listed Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis

Innovaderm September 2016 – December 2016

Protocol BPX-01-C03: Phase 2b, multicentre, double-blind, randomized, three arm, vehicle-controlled study evaluating the reduction in inflammatory lesions in subjects aged 9 to 40 years old with moderate to severe inflammatory non-nodular acne vulgaris over 12 weeks of topical treatment

Symbio November 2016 – Oct 2017

Protocol PRG-NY-16-009: A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo UK FINCO's Azelaic Acid Foam, 15%, to Bayer Healthcare Pharmaceutical Inc.'s, FINACEA® (AZELAIC ACID) FOAM, 15%, and Both Active Treatments to a Vehicle Control in the Treatment of Inflammatory Lesions of Rosacea

Menlo Therapeutics February 2017- April 2018

Protocol MTI-103: A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis

Dr.Reddy's April 2017- December 2017

Protocol DFD-07-CD-002: A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Evaluate the Dose-Response Relationship of the Efficacy and Safety of Two Concentrations of DFD-07 (celecoxib) Cream, in Subjects with Actinic Keratosis (AK) of the Face and Scalp Over a 12-week Treatment Period

Ralexar Therapeutics April 2017- June 2018

Protocol ALX-101-ATOP-202: A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of a Topical Gel Administered Twice Daily in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis. *Seemal R. Desai, MD, FAAD ACRC Trials, Updated 12JAN2021*

Dr. Reddy's Laboratories October 2017- July 2018

DFD-03-CD-005: A Multicenter Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

Menlo Therapeutics April 2018- November 2018

Protocol MTI-109: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults with Plaque Psoriasis

Sol-Gel Technologies July 2018- March 2019

Protocol SGT-54-01: A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Ralexar Therapeutics May 2018 – June 2018

Protocol ALX-101-ATOP-203: Pilot study to explore LXR recept engagement by ALX-101 following treatment of moderate atopic dermatitis with ALX-101 topical gel and vehicle gel

Sol-Gel Technologies November 2018- October 2019

Protocol SGT-54-07: A Multi-Center, Open-Label, Long-Term Safety Study of S5G4T-1 to Evaluate the Safety of S5G4T-1 in Papulopustular Rosacea Patients

Dermira February 2019- May 2019

Protocol DRM04-HH10: A phase 2, randomized, double-blind, vehicle-controlled efficacy and safety study of glycopyrronium cloth, 2.4% in patients with palmar hyperhidrosis

Novan June 2019 – August 2019

Protocol NI-MC302: A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum

Dermavant July 2019 – November 2020

Protocol DMVT-505-3002: A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

Dermavant November 2019 - Present

Protocol DMVT-505-3003: A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults

Atacama February 2020 - Present

Protocol 217-9951-202: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects with Moderate to Severe Palmar Hyperhidrosis

AO Biome June 2019 - Present

Protocol PRB244-01: A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritis in Adults with a History of Atopic Dermatitis *Seemal R. Desai, MD, FAAD ACRC Trials, Updated 12JAN2021*

Incyte August 2019 - Present

Protocol INCB 18424-306: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants with Vitiligo

Incyte November 2020 - Present

Protocol INCB 18424-308: A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo

Bibliography

Peer-Reviewed

Original Research Articles

1.	Desai, SR. Choosing a field of medicine: a medical student's perspective. <i>J Med Assoc Ga.</i> 2004;93(3):34.
2.	Desai, SR. The benefit and burden of ancillary professionals in dermatology. <i>Virtual Mentor.</i> 2006 Aug 1;8(8):514-6. doi: 10.1001/virtualmentor.2006.8.8.jdsc1-0608
3.	Swanson AM, Desai SR, Jackson JD, Andea AA, Hughey LC. Calciphylaxis associated with chronic inflammatory conditions, immunosuppression therapy, and normal renal function: a report of 2 cases. <i>Arch Dermatol.</i> 2009 Jun;145(6):723-5. doi:10.1001/archdermatol.2009.103.
4.	Desai SR. Hyperpigmentation Therapy: A Review. <i>J Clin Aesthet Dermatol.</i> 2014 Aug;7(8):13-7.
5.	Desai SR, Owen JL. Progressive macular hypomelanosis: An update. <i>Pigment International.</i> 2015 Jan;1(2):52-55.
6.	Owen JL, Lopez IE, Desai SR. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. <i>J Drugs Dermatol.</i> 2015;14(5):509-10.
7.	Eichenfield LF, Del Rosso JQ, Mancini AJ, Cook-Bolden F, Stein Gold L, Desai S, Weiss J, Pariser D, Zeichner J, Bhatia N, Kircik L. Evolving perspectives on the etiology and pathogenesis of acne vulgaris. <i>J Drugs Dermatol.</i> 2015 Mar;14(3):263-72. Review. PubMed PMID: 25738848.
8.	Desai SR. Protecting Dermatology-Advocating for Our Future. <i>J Clin Aesthet Dermatol.</i> 2015 Jul;8(7):10-1. PubMed PMID: 26203315; PubMed Central PMCID: PMC4509580.
9.	Desai SR, Frieden IJ, Gelfand JM, High W, Kavanaugh A, Marghoob AA, Ozog DM, Rosen T, Stein Gold L, Strober B, Swanson N, Martin G. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. <i>J Clin Aesthet Dermatol.</i> 2015 Sep;8(9 Suppl):S4-S26. PubMed PMID: 26504503; PubMed Central PMCID: PMC4591555.
10.	Harker DB, Turrentine JE, Desai SR. Vulvar Asymmetry Due to Silicone Migration and Granulomatous Immune Response Following Injection for Buttock Augmentation. <i>J Clin Aesthet Dermatol.</i> 2017 Apr;10(4):50-54
11.	Kailas A, Botwin A, Pritchett EN, Jackson-Richards D, Lewis S, Sathwani D, Desai SR, Taylor SC. Assessing the Effectiveness of Knowledge-Based Interventions in Increasing Skin Cancer Awareness, Knowledge, and Protective Behavior Among People of Color. <i>Cutis.</i> 2017 Oct;100(4):235-40. PubMed PMID: 29136057
12.	Quertermous J, Desai S, Harper J, Lebwohl M, Torres A, Kircik LH. <i>The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.</i> <i>J Drugs Dermatol.</i> 2018 Jul 1;17(7):s17-s22.
13.	Desai SR, Hernandez C, McMichael AJ. Spectrum of Diversity in Dermatology: The need to Broaden Clinical Trial Participants in Our Increasingly Multiethnic and Multicultural Society. <i>JAMA Dermatol.</i> 2017 Jan 4. doi: 10.1001/jamadermatol.2016.4130. [Epub ahead of print] PubMed PMID: 28055061.
14.	Harker DB, Turrentine JE, Desai SR. Vulvar Asymmetry Due to Silicone Migration and Granulomatous Immune Response Following Injection for Buttock Augmentation. <i>J Clin Aesthet Dermatol.</i> 2017 Apr;10(4):50-54. PubMed PMID: 28458775; PubMed Central PMCID: PMC5404781.

15.	Kailas A, Botwin A, Pritchett EN, Jackson-Richards D, Lewis S, Sathwani D, Desai SR , Taylor SC. Assessing the Effectiveness of Knowledge-Based Interventions in Increasing Skin Cancer Awareness, Knowledge, and Protective Behavior Among People of Color. <i>Cutis</i> . 2017 Oct;100(4):235-40. PubMed PMID: 29136057
16.	Alexis A, Del Rosso JQ, Desai SR , et al. BPX-01 Minocycline Topical Gel Shows Promise for the Treatment of Moderate-to-severe Inflammatory Acne Vulgaris. <i>J Clin Aesthet Dermatol</i> . 2018;11(11):25-35.
17.	McMichael, A., Desai, SR , Qureshi, A. et al. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials. <i>Am J Clin Dermatol</i> (2018). https://doi.org/10.1007/s40257-018-0408-z
18.	Alexis, A, Callender, V, Baldwin, HE, Desai, SR et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. <i>J Am Acad Dermatol</i> . 2018 Sep 19. pii: S0190-9622(18)32576-3. doi: 10.1016/j.jaad.2018.08.049
19.	McMichael A, Desai SR , Qureshi A, Rastogi S, Alexis AF. Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: results from the pooled AMAGINE-2/-3 randomized trials. <i>Am J Clin Dermatol</i> . 2019;20(2):267-276. https://www.ncbi.nlm.nih.gov/pubmed/30471012
20.	Ezekor, M., & Desai, S. (2019). How to Manage Melasma. <i>SKIN The Journal of Cutaneous Medicine</i> , 3(3), 176-179. doi: https://jofskin.org/index.php/skin/article/view/600
21.	Desai SR . Therapeutic Hotline: The Latest and Greatest in Dermatology. <i>Dermatol Clin</i> . 2019 Apr;37(2):ix. doi: 10.1016/j.det.2019.01.001. Epub 2019 Feb 13
22.	Desai S , Ayres E, Bak H, Manco M, Lynch S, Raab S, Du A, Green D, Skobowiat C, Wangari-Talbot J, Zheng Q. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation. <i>J Drugs Dermatol</i> . 2019 May 1;18(5):454-459.
23.	Callender V, Alexis AF, Stein Gold LF, Lebwohl MG, Paller AS, Desai SR , Tan H, Ports WC, Zielinski MA, Tallman, A. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. <i>Am J Clin Dermatol</i> . 2019 Oct;20(5):711-723. doi: 10.1007/s40257-019-00450-w.
24.	Han G, Armstrong AW, Desai SR , Guenin E. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population. <i>J Drugs Dermatol</i> . 2019 Sep 1;18(9):910-916.
25.	Alexis A, Yamauchi P, Desai S , Khaselev N, Lin, T. Efficacy, Safety, and Tolerability of Halobetasol Propionate 0.01%–Tazarotene 0.045% Lotion for Moderate to Severe Plaque Psoriasis in the Hispanic Population: Post Hoc Analysis. <i>Cutis</i> . 2020;105(3):150-155;E3-E4.
26.	Alexis AF, Desai SR , Jacobson A. Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report. <i>J Drugs Dermatol</i> . 2020;19(10):1000-1004.
27.	Desai SR , Kovarik C, Brod B, James W, Fitzgerald ME, Preston A, Hruza GJ. COVID-19 and personal protective equipment: Treatment and prevention of skin conditions related to the occupational use of personal protective equipment. <i>J Am Acad Dermatol</i> . 2020 Aug;83(2):675-677. doi: 10.1016/j.jaad.2020.05.032. Epub 2020 May 15. PMID: 32416206; PMCID: PMC7228687.
28.	Desai SR , Glick B, Del Rosso JQ, Lin T. Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. <i>SKIN: The Journal of Cutaneous Medicine</i> . 2020;4(1): S8

29.	Del Rosso J, Gold LS, Kircik L., Alexis A., Desai SR. , Stakias V., & Stuart I. (2020). Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients. <i>SKIN The Journal of Cutaneous Medicine</i> , 4(6), s89. https://doi.org/10.25251/skin.4.suppl.89
30.	Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR , Harp J, Takeshita J, French LE, Lim HW, Thiers BH, Hruza GJ, Fox LP. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. <i>J Am Acad Dermatol</i> . 2020 Oct;83(4):1118-1129. doi: 10.1016/j.jaad.2020.06.1016. Epub 2020 Jul 2. PMID: 32622888; PMCID: PMC7331510.
31.	Desai SR , Glick B, Del Rosso JQ, Harris S, Jacobson A. Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants. <i>J Drugs Dermatol</i> . In press.
32.	Eichenfield L, Hebert A, Desai SR , Ghali F, Levy ML, Mancini AJ, Rice Z, Sugarman J, Zaenglein A. The new face of preadolescent and adolescent acne: Beyond the guidelines. Journal submission: TBD.
33.	Desai SR . Hair Stylists as Screeners for Scarring Hair Loss Within the African American Community: A Cross Sectional Study. PracticeUpdate website. Available at: Hair Stylists as Screeners for Scarring Hair Loss Within the African American Community. Accessed February 17, 2021

Reviews, Chapters, Monographs and Editorials

1.	Desai SR , Sarkar R. Fungal Diseases. In: Sarkar R, Desai SR (editors): <i>World Clinics in Dermatology: Fungal infections of the skin</i> ; Jaypee Brothers Medical Publishers, New Delhi, 2016;(3)1:1-2.
2.	Desai SR , Jha AK, Sarkar R. Use of moisturizers for conditions of hyperpigmentation. In: Sarkar (ed.): <i>Moisturisers</i> ; Jaypee Brothers Medical Publishers, New Delhi, First Edition. 2016;pp-100-104.
3.	Desai SR , Sarkar R, Ailawadi P, Prier K. Management of Dyspigmentation. In: Lawrence, N and Kantor, J (eds). <i>Dermatologic Surgery</i> . McGraw-Hill. March 2018. 1st ed.
4.	Desai, SR , Stewart, J.R. Mandelic acid peels.. Sarkar R., Roberts W. (eds). <i>Chemical Peels: A global perspective</i> . Jaypee Brothers Publishers Pvt Ltd.. 2019. pp. 78-81.
5.	Desai, SR , Ghunawat, S. Hypopigmented Disorders. In Lebwohl, MG, Heymann, W, Berth-Jones, J. and Coulson, (eds), <i>Treatment of Skin Disease: Comprehensive Therapeutic Strategies</i> . 5th ed, Ch 111; 2018 pp: 362-364
6.	Desai, SR , Ghunawat, S. Postinflammatory Hyperpigmentation and Other Disorders of Hyperpigmentation. In Lebwohl, MG, Heymann, W, Berth-Jones, J. and Coulson, I (eds), <i>Treatment of Skin Disease: Comprehensive Therapeutic Strategies</i> . 5th ed, Ch 200; 2018 pp: 658-661
7.	Desai, SR , Umeh, O. Sensitive Skin – Aesthetic Approach in Skin of Color . In Sachdev, M, Khunger, N: <i>Essentials in Ethnic Skin</i> . 1 st ed. 2019. (in press)

Case Reports & Poster Presentations

1.	Stein Gold L, Desai SR , Bhatia N, Makori M, Jacobson A. Fixed-combination halobetasol propionate and tazarotene lotion reduces signs and symptoms of psoriasis in patients with
----	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	body surface area involvement of 3% to 5%. Poster presented at: Innovations in Dermatology: Virtual Spring Conference; March 16-20, 2021.
2.	Alexis AF, Desai SR , Kerby E, Jacobson A. Efficacy and Safety of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Plaque Psoriasis: Post Hoc Analysis of Non-White and White Participants From Two Phase 3 Studies. Abstract Submitted to Skin of Color Scientific Symposium. March 2021.
3.	Grimes P, Desai SR , Huggins RH, Lebwohl M, Passeron T, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Ezzedine K, Harris J, Pandya AG, Butler K, Kuo FI, Sun K, Rosmarin D. Demographics and baseline clinical characteristics of patients enrolled in 2 randomized, double-blind, phase 3 studies of ruxolitinib cream for the treatment of vitiligo. Presented at: Global Vitiligo Foundation Symposium; March 20, 2021
4.	Kircik L, Lebwohl M, Bhatia N, Zirwas M, Desai SR , Brown P, Tallman A, Somerville M, Piscitelli S, Rubenstein D. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Favorable Local Tolerability in Two Pivotal Phase 3 Trials. Poster to be presented at the Maui Derm for Dermatologists 2021 Meeting.
5.	Del Rosso, J, Gold, LS, Kircik, L., Alexis, A., Desai, SR , Stakias, V., & Stuart, I. (2020). Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients. Presented at Winter Clinical 2021.
6.	Han G, Armstrong AW, Desai SR , Guenin E. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Asians. <i>SKIN: The Journal of Cutaneous Medicine</i> . 2020;4(1): S16
7.	Del Rosso, J, Gold, LS, Kircik, L., Alexis, A., Desai, SR , Stakias, V., & Stuart, I. (2020). Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients. Presented at Fall Clinical 2020.
8.	Desai SR , Glick B, Del Rosso JQ, Guenin E, Lin T. Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. Poster Presented at ODAC Dermatology, Aesthetic & Surgical Conference. January 2020.
9.	Desai SR , Glick B, Del Rosso JQ, Lin T. Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. Poster Presented at Maui Derm for Dermatologists. January 2020.
10.	Desai SR , Glick B, Del Rosso JQ, Lin T. Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. Poster Presented at the 44th Annual Hawaii Dermatology Seminar. February 2020.
11.	Desai SR , Glick B, Del Rosso JQ, Guenin E, Lin T. Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. Poster Presented at Skin of Color Scientific Symposium. May 2020.
12.	Desai SR , Glick B, Del Rosso JQ, Jacobson A. Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. Poster Presented at Skin of Color Update. September 2020.
13.	Stein Gold L, Weiss J, Draelos Z, Desai SR , Stakias V, Stuart I, Open-Label Extension Study Evaluating the Long-Term Efficacy and Safety of FMX101 4% Topical Minocycline Foam in

	the Treatment of Moderate-to-Severe Acne Vulgaris: Results From Two Phase III Studies. Poster Presented at 2020 Coastal Derm Virtual Meeting, October 2020.
14.	Alexis A, Desai SR , Sangha A, Jacobson A. Effects of brodalumab on quality of life measured by Short Form 36 version 2 in patients with psoriasis and skin of color. Skin of Color Update 2019; September 7-8, 2019; New York, NY.
15.	Bhatia ND, Desai SR , Teller C, Jacobson A. Maintenance and improvement of skin clearance response with brodalumab among patients with moderate-to-severe psoriasis. 39th Annual Fall Clinical Dermatology Conference® for Dermatologists; October 17-20, 2019; Las Vegas, NV
16.	Han G, Armstrong AW, Desai SR , Mosenson J, Guenin E. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population. Poster Presented at SDEF's 20th Annual Las Vegas Dermatology Seminar. November 2019.
17.	Han G, Armstrong AW, Desai SR , Guenin E. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population. <i>SKIN: The Journal of Cutaneous Medicine</i> . 2019;3: S5
18.	Owen JL, Word AP, Vandergriff T, Desai SR . Paraneoplastic plaque-like cutaneous mucinosis: a case report. <i>Dermatol Online J</i> . 2015;21(2):5.
19.	Kailas A, Desai SR, Pritchett EN, Jakus J.. (March, 2017). Investigating the Psychosocial Impact of Vitiligo by Fitzpatrick Skin Type Using a Facebook Survey and VitiQoL: Do Patients with Darker Skin Have Worse Impact? Poster presented at: 2017 Global Vitiligo Foundation Annual Pre-AAD Meeting; Orlando, FL, USA.
20.	Kailas A, Solomon JA, Jakus J, Rigel DS, Pritchett EN, Desai SR, Taylor SC. (March, 2017). A Social Media Survey to Assess Knowledge, Behavior, and Patient Satisfaction Regarding Skin Cancer Among the Skin of Color Population. Oral Presentation presented at: Skin of Color Society Annual Pre-AAD Meeting; Orlando, FL, USA.

Non-peer reviewed scientific or medical publications/materials in print or other media

1.	Desai, S . Tips for Topical Management of Localized Pigmentation. <i>Modern Aesthetics</i> . July/August 2013:18-19.
2.	Desai, S . Management Options for Hyperpigmentation: An Update. <i>Practical Dermatology</i> . June 2013:27-29.
3.	Desai, S . Physician Focus. <i>Practical Dermatology</i> . May 2014:66.
4.	Desai, S . Dyschromia Management: The Case for Depigmentation. <i>Practical Dermatology</i> . June 2014:21-25.
5.	Desai, SR . Handling Gossip in the Workplace. <i>Dermatology World Young Physician Focus</i> . Summer 2014, p.4.
6.	Kailas A, Solomon JA, Rigel DS, Mostow EN, Jackson-Richards D, Pritchett EN, Desai SR , Taylor SC. Lack of Native American Inclusion in Skin Cancer Research. <i>Skin</i> . 2017, Aug; Accepted.
7.	New York Times. "A New Skin Lightening Procedure is Short on Evidence." August 28, 2017. https://www.nytimes.com/2017/08/28/health/skin-lightening-glutathione-bleaching.html?utm_source=Media+Newsletters&utm_campaign=8533e7955a-17-037-CMM-Media-update_2017_07_10&utm_medium=email&utm_term=0_fe6800c545-8533e7955a-60849285&mc_cid=8533e7955a&mc_eid=e3b1038290

8.	Highya.com. "Experts Warn Against Intravenous Glutathione Treatments for Skin Lightening". September 9, 2017. https://www.highya.com/articles-guides/experts-warn-against-intravenous-glutathione-treatments-for-skin-lightening
9.	Dermatology Times. June 2018. New Treatment approaches to Melasma. Desai SR https://www.dermatologytimes.com/dermatology/new-treatments-and-approaches-melasma
10.	MedEsthetics. "A Guiding Hand". https://www.medestheticsmag.com/guiding-hand
11.	Smithsonian Mag. July 16, 2018. Can We Create Sunscreen That Protects Both Humans and Coral Reefs? Desai SR . https://www.smithsonianmag.com/science/scientists-are-unraveling-new-dangers-sunscreen-coral-reefs-180969627/
12.	Mic.com. People of Color and Sunscreen. Desai SR. https://mic.com/articles/190298/skincare-sunscreen-brands-for-people-of-color-darker-skin-tones#.mR7BU9is7
13.	DermTube.com. Journal Club. Melasma Matters. www.dermtube.com
14.	Racked. Jul 11, 2018. Lip Fillers https://www.racked.com/2018/7/11/17561766/kylie-jenner-lip-fillers-injections-dissolving-dermatologist
15.	US News & World Report Health. June 20, 2018. Desai SR . https://health.usnews.com/health-care/patient-advice/articles/preventing-and-treating-poison-ivy
16.	Dermatology Times. Skin of Color Seminar Series. Desai SR . https://www.dermatologytimes.com/dermatology/skin-color-seminar-series-roundup
17.	The Dermatologist. April 26, 2018. Skin of Color Treatment Recommendations. Desai SR . https://www.the-dermatologist.com/article/skin-color-treatment-considerations?eclick=b
18.	HealthDay. February 5, 2018. New Treatment Could be Breakthrough for Vitiligo. Desai SR . https://consumer.healthday.com/diseases-and-conditions-information-37/vitiligo-1004/new-treatment-could-be-breakthrough-for-vitiligo-skin-condition-730807.html
19.	UAB Department of Dermatology. Winter 2018 Newsletter. Seemal R. Desai MD article "Keeping up with Seemal"
20.	Self.com. "Why am I getting these tiny black moles on my face?" Desai SR. https://www.self.com/story/dermatosis-papulosa-nigra?mc_cid=8c7423db6b&mc_eid=e3b1038290
21.	Next Steps in Derm. Difficult Staff- Tips for Handling the Challenge September 2018. https://nextstepsinderm.com/navigating-your-career/running-a-practice/difficult-staff-tips-for-handling-the-challenge/